385 related articles for article (PubMed ID: 31187421)
1. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
Linette GP; Carreno BM
Curr Hematol Malig Rep; 2019 Aug; 14(4):286-291. PubMed ID: 31187421
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
4. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Yamashita H; Nakayama K; Ishikawa M; Ishibashi T; Nakamura K; Sawada K; Yoshimura Y; Tatsumi N; Kurose S; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623180
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
10. LIGHT May Improve Immune Checkpoint Blockade Response.
Cancer Discov; 2016 Jun; 6(6):OF9. PubMed ID: 27080334
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
12. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
13. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Hosoi A; Takeda K; Nagaoka K; Iino T; Matsushita H; Ueha S; Aoki S; Matsushima K; Kubo M; Morikawa T; Kitaura K; Suzuki R; Kakimi K
Sci Rep; 2018 Jan; 8(1):1058. PubMed ID: 29348598
[TBL] [Abstract][Full Text] [Related]
14. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
[TBL] [Abstract][Full Text] [Related]
15. Current status of immunotherapy for gastrointestinal stromal tumor.
Tan Y; Trent JC; Wilky BA; Kerr DA; Rosenberg AE
Cancer Gene Ther; 2017 Mar; 24(3):130-133. PubMed ID: 28186088
[TBL] [Abstract][Full Text] [Related]
16. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
17. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
18. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M
Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991
[No Abstract] [Full Text] [Related]
19. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
20. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
Sabio E; Chan TA
Genome Med; 2019 Jul; 11(1):43. PubMed ID: 31340855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
